Works by Wiesweg, Marcel

Results: 34

Acquired Resistance to BRAF/MEK Inhibitor Therapy in BRAF-V600-mutated Squamous Cell Lung Cancer: Concurrent Evolvement of PTEN and MEK1 Mutations.

Published in:

Clinical Lung Cancer, 2021, v. 22, n. 5, p. e668, doi. 10.1016/j.cllc.2020.11.008

By:

Metzenmacher, Martin;
Goetz, Moritz;
Herold, Thomas;
Stuschke, Martin;
Aigner, Clemens;
Darwiche, Kaid;
Eberhardt, Wilfried E.;
Schuler, Martin;
Wiesweg, Marcel

Publication type:

Article

Rapid and Highly Sensitive Detection of Therapeutically Relevant Oncogenic Driver Mutations in EBUS-TBNA Specimens From Patients With Lung Adenocarcinoma.

Published in:

2018

By:

Oezkan, Filiz;
Herold, Thomas;
Darwiche, Kaid;
Eberhardt, Wilfried E E;
Worm, Karl;
Christoph, Daniel C;
Wiesweg, Marcel;
Freitag, Lutz;
Schmid, Kurt-Werner;
Theegarten, Dirk;
Hager, Thomas;
Koenig, Michael J;
He, Kai;
Taube, Christian;
Schuler, Martin;
Breitenbuecher, Frank

Publication type:

journal article

Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting.

Published in:

Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 11, p. 9243, doi. 10.1007/s00432-023-04839-3

By:

Kraskowski, Oliver;
Stratmann, Jan A.;
Wiesweg, Marcel;
Eberhardt, Wilfried;
Metzenmacher, Martin;
Schmid, Kurt W.;
Herold, Thomas;
Schildhaus, Hans-Ulrich;
Darwiche, Kaid;
Aigner, Clemens;
Stuschke, Martin;
Laue, Katharina;
Zaun, Gregor;
Kasper, Stefan;
Hense, Jörg;
Sebastian, Martin;
Schuler, Martin;
Pogorzelski, Michael

Publication type:

Article

Identification of a new prognostic score for patients with high-grade metastatic GEP-NEN treated with palliative chemotherapy.

Published in:

Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 8, p. 4315, doi. 10.1007/s00432-022-04314-5

By:

Rosery, Vivian;
Mika, Stephan;
Schmid, Kurt Werner;
Reis, Henning;
Stuschke, Martin;
Treckmann, Jürgen;
Markus, Peter;
Schumacher, Brigitte;
Albers, David;
Mende, Bastian;
Lahner, Harald;
Wiesweg, Marcel;
Schuler, Martin;
Siveke, Jens T.;
Kasper, Stefan

Publication type:

Article

Improved survival in metastatic breast cancer: results from a 20-year study involving 1033 women treated at a single comprehensive cancer center.

Published in:

Journal of Cancer Research & Clinical Oncology, 2020, v. 146, n. 6, p. 1559, doi. 10.1007/s00432-020-03184-z

By:

Welt, Anja;
Bogner, Simon;
Arendt, Marina;
Kossow, Josef;
Huffziger, Antonia;
Pohlkamp, Christian;
Steiniger, Heike;
Becker, Ute;
Alashkar, Ferras;
Kohl, Marzena;
Wiesweg, Marcel;
Richly, Heike;
Hense, Jörg;
Scheulen, Max E.;
Schuler, Martin;
Seeber, Siegfried;
Tewes, Mitra

Publication type:

Article

Patterns of nodal spread in stage III NSCLC: importance of EBUS-TBNA and 18F-FDG PET/CT for radiotherapy target volume definition.

Published in:

2021

By:

Guberina, Maja;
Darwiche, Kaid;
Hautzel, Hubertus;
Pöttgen, Christoph;
Guberina, Nika;
Gauler, Thomas;
Ploenes, Till;
Umutlu, Lale;
Theegarten, Dirk;
Aigner, Clemens;
Eberhardt, Wilfried E. E.;
Metzenmacher, Martin;
Wiesweg, Marcel;
Karpf-Wissel, Rüdiger;
Schuler, Martin;
Herrmann, Ken;
Stuschke, Martin

Publication type:

journal article

Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2024: Targeted Therapies in Non-Small Cell Lung Cancer.

Published in:

2025

By:

Webendörfer, Maximilian;
Heinzen, Sophie;
Sibbert, Christine;
Leßmann, Marie-Elisabeth;
Kropf-Sanchen, Cornelia;
Thomas, Michael;
Tufman, Amanda;
Bleckmann, Annalen;
Wiesweg, Marcel;
Griesinger, Frank;
Reitnauer, Lea;
Overbeck, Tobias Raphael

Publication type:

Letter

A Phase II Study of Nab-Paclitaxel and Gemcitabine as First-Line Therapy in Patients with Cholangiocarcinoma Ineligible for Cisplatin-Based Chemotherapy (NACHO).

Published in:

Oncology Research & Treatment, 2023, v. 46, n. 3, p. 89, doi. 10.1159/000529012

By:

Virchow, Isabel;
Treckmann, Jürgen-Walter;
Prasnikar, Nicole;
Linden, Gabriele;
Markus, Peter;
Schumacher, Brigitte;
Albers, David;
Herold, Thomas;
Ting, Saskia;
Schmidt, Hartmut;
Radunz, Sonja;
Wiesweg, Marcel;
Siveke, Jens;
Schuler, Martin;
Kasper, Stefan

Publication type:

Article

Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas.

Published in:

International Journal of Cancer, 2018, v. 143, n. 7, p. 1764, doi. 10.1002/ijc.31547

By:

Reis, Henning;
van der Vos, Kristan E.;
Niedworok, Christian;
Herold, Thomas;
Módos, Orsolya;
Szendrői, Attila;
Hager, Thomas;
Ingenwerth, Marc;
Vis, Daniël J.;
Behrendt, Mark A.;
de Jong, Jeroen;
van der Heijden, Michiel S.;
Peyronnet, Benoit;
Mathieu, Romain;
Wiesweg, Marcel;
Ablat, Jason;
Okon, Krzysztof;
Tolkach, Yuri;
Keresztes, David;
Nagy, Nikolett

Publication type:

Article

Fibroblast Activation Protein–Directed Imaging Outperforms 18F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial.

Published in:

Journal of Nuclear Medicine, 2024, v. 65, n. 8, p. 1188, doi. 10.2967/jnumed.124.267473

By:

Kessler, Lukas;
Schwaning, Felix;
Metzenmacher, Martin;
Pabst, Kim;
Siveke, Jens;
Trajkovic-Arsic, Marija;
Schaarschmidt, Benedikt;
Wiesweg, Marcel;
Aigner, Clemens;
Plönes, Till;
Darwiche, Kaid;
Bölükbas, Servet;
Stuschke, Martin;
Umutlu, Lale;
Nader, Michael;
Theegarten, Dirk;
Hamacher, Rainer;
Eberhardt, Wilfried E.E.;
Schuler, Martin;
Herrmann, Ken

Publication type:

Article

Early Metabolic Response by PET Predicts Sensitivity to Next-Line Targeted Therapy in EGFR-Mutated Lung Cancer with Unknown Mechanism of Acquired Resistance.

Published in:

Journal of Nuclear Medicine, 2024, v. 65, n. 6, p. 851, doi. 10.2967/jnumed.123.266979

By:

Schuler, Martin;
Hense, Jörg;
Darwiche, Kaid;
Michels, Sebastian;
Hautzel, Hubertus;
Kobe, Carsten;
Lueong, Smiths;
Metzenmacher, Martin;
Herold, Thomas;
Zaun, Gregor;
Laue, Katharina;
Drzezga, Alexander;
Theegarten, Dirk;
Nensa, Felix;
Wolf, Jürgen;
Herrmann, Ken;
Wiesweg, Marcel

Publication type:

Article

68Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study.

Published in:

Journal of Nuclear Medicine, 2023, v. 64, n. 10, p. 1540, doi. 10.2967/jnumed.123.265664

By:

Kersting, David;
Sandach, Patrick;
Sraieb, Miriam;
Wiesweg, Marcel;
Metzenmacher, Martin;
Darwiche, Kaid;
Oezkan, Filiz;
Bölukbas, Servet;
Stuschke, Martin;
Umutlu, Lale;
Nader, Michael;
Hamacher, Rainer;
Fendler, Wolfgang P.;
Wienker, Johannes;
Eberhardt, Wilfried E. E.;
Schuler, Martin;
Herrmann, Ken;
Hautzel, Hubertus

Publication type:

Article

SUVmax Above 20 in 18F-FDG PET/CT at Initial Diagnostic Workup Associates with Favorable Survival in Patients with Cancer of Unknown Primary.

Published in:

Journal of Nuclear Medicine, 2023, v. 64, n. 8, p. 1191, doi. 10.2967/jnumed.122.265161

By:

Zaun, Gregor;
Weber, Manuel;
Metzenmacher, Martin;
Wiesweg, Marcel;
Hilser, Thomas;
Zaun, Yasmin;
Liffers, Sven;
Pogorzelski, Michael;
Virchow, Isabel;
Eberhardt, Wilfried;
Theurer, Sarah;
Sabbah, Tanja Abu;
Reissig, Timm M.;
Stuschke, Martin;
Kürten, Cornelius;
Hussain, Timon;
Lang, Stephan;
Kasper, Stefan;
Fendler, Wolfgang P.;
Herrmann, Ken

Publication type:

Article

PROGNOSTIC VALUE OF POST-INDUCTION CHEMOTHERAPY VOLUMETRIC PET/CT PARAMETERS FOR STAGE IIIA/B NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING DEFINITIVE CHEMORADIOTHERAPY.

Published in:

Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.120.260646

By:

Guberina, Maja;
Pöttgen, Christoph;
Metzenmacher, Martin;
Wiesweg, Marcel;
Schuler, Martin;
Aigner, Clemens;
Ploenes, Till;
Umutlu, Lale;
Gauler, Thomas;
Darwiche, Kaid;
Stamatis, Georgios;
Theegarten, Dirk;
Hautzel, Hubertus;
Jentzen, Walter;
Guberina, Nika;
Herrmann, Ken;
Eberhardt, Wilfried E. E.;
Stuschke, Martin

Publication type:

Article

PROGNOSTIC VALUE OF POST-INDUCTION CHEMOTHERAPY VOLUMETRIC PET/CT PARAMETERS FOR STAGE IIIA/B NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING DEFINITIVE CHEMORADIOTHERAPY.

Published in:

Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.120.260646

By:

Guberina, Maja;
Pöttgen, Christoph;
Metzenmacher, Martin;
Wiesweg, Marcel;
Schuler, Martin;
Aigner, Clemens;
Ploenes, Till;
Umutlu, Lale;
Gauler, Thomas;
Darwiche, Kaid;
Stamatis, Georgios;
Theegarten, Dirk;
Hautzel, Hubertus;
Jentzen, Walter;
Guberina, Nika;
Herrmann, Ken;
Eberhardt, Wilfried E. E.;
Stuschke, Martin

Publication type:

Article

PROGNOSTIC VALUE OF POST-INDUCTION CHEMOTHERAPY VOLUMETRIC PET/CT PARAMETERS FOR STAGE IIIA/B NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING DEFINITIVE CHEMORADIOTHERAPY.

Published in:

Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.120.260646

By:

Guberina, Maja;
Pöttgen, Christoph;
Metzenmacher, Martin;
Wiesweg, Marcel;
Schuler, Martin;
Aigner, Clemens;
Ploenes, Till;
Umutlu, Lale;
Gauler, Thomas;
Darwiche, Kaid;
Stamatis, Georgios;
Theegarten, Dirk;
Hautzel, Hubertus;
Jentzen, Walter;
Guberina, Nika;
Herrmann, Ken;
Eberhardt, Wilfried E. E.;
Stuschke, Martin

Publication type:

Article

PROGNOSTIC VALUE OF POST-INDUCTION CHEMOTHERAPY VOLUMETRIC PET/CT PARAMETERS FOR STAGE IIIA/B NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING DEFINITIVE CHEMORADIOTHERAPY.

Published in:

Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.120.260646

By:

Guberina, Maja;
Pöttgen, Christoph;
Metzenmacher, Martin;
Wiesweg, Marcel;
Schuler, Martin;
Aigner, Clemens;
Ploenes, Till;
Umutlu, Lale;
Gauler, Thomas;
Darwiche, Kaid;
Stamatis, Georgios;
Theegarten, Dirk;
Hautzel, Hubertus;
Jentzen, Walter;
Guberina, Nika;
Herrmann, Ken;
Eberhardt, Wilfried E. E.;
Stuschke, Martin

Publication type:

Article

PROGNOSTIC VALUE OF POST-INDUCTION CHEMOTHERAPY VOLUMETRIC PET/CT PARAMETERS FOR STAGE IIIA/B NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING DEFINITIVE CHEMORADIOTHERAPY.

Published in:

Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.120.260646

By:

Guberina, Maja;
Pöttgen, Christoph;
Metzenmacher, Martin;
Wiesweg, Marcel;
Schule, Martin;
Aigner, Clemens;
Ploenes, Till;
Umutlu, Lale;
Gauler, Thomas;
Darwiche, Kaid;
Stamatis, Georgios;
Theegarten, Dirk;
Hautzel, Hubertus;
Jentzen, Walter;
Guberina, Nika;
Herrmann, Ken;
Eberhardt, Wilfried E. E.;
Stuschke, Martin

Publication type:

Article

PROGNOSTIC VALUE OF POST-INDUCTION CHEMOTHERAPY VOLUMETRIC PET/CT PARAMETERS FOR STAGE IIIA/B NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING DEFINITIVE CHEMORADIOTHERAPY.

Published in:

Journal of Nuclear Medicine, 2021, v. 62, n. 6, p. 31, doi. 10.2967/jnumed.120.260646

By:

Guberina, Maja;
Pöttgen, Christoph;
Metzenmacher, Martin;
Wiesweg, Marcel;
Schuler, Martin;
Aigner, Clemens;
Ploenes, Till;
Umutlu, Lale;
Gauler, Thomas;
Darwiche, Kaid;
Stamatis, Georgios;
Theegarten, Dirk;
Hautzel, Hubertus;
Jentzen, Walter;
Guberina, Nika;
Herrmann, Ken;
Eberhardt, Wilfried E. E.;
Stuschke, Martin

Publication type:

Article

Long-Term Survival in Patients with Oligometastatic Non-Small Cell Lung Cancer by a Multimodality Treatment—Comparison with Stage III Disease.

Published in:

Cancers, 2024, v. 16, n. 6, p. 1174, doi. 10.3390/cancers16061174

By:

Guberina, Maja;
Pöttgen, Christoph;
Guberina, Nika;
Hoffmann, Christian;
Wiesweg, Marcel;
Richlitzki, Cedric;
Metzenmacher, Martin;
Aigner, Clemens;
Bölükbas, Servet;
Gauler, Thomas;
Eberhardt, Wilfried E. E.;
Forsting, Michael;
Herrmann, Ken;
Theegarten, Dirk;
Darwiche, Kaid;
Jendrossek, Verena;
Stuschke, Martin;
Schuler, Martin

Publication type:

Article

Electronic Patient-Reported Outcome Measures (ePROMs) Improve the Assessment of Underrated Physical and Psychological Symptom Burden among Oncological Inpatients.

Published in:

Cancers, 2023, v. 15, n. 11, p. 3029, doi. 10.3390/cancers15113029

By:

Warnecke, Eva;
Salvador Comino, Maria Rosa;
Kocol, Dilara;
Hosters, Bernadette;
Wiesweg, Marcel;
Bauer, Sebastian;
Welt, Anja;
Heinzelmann, Anna;
Müller, Sandy;
Schuler, Martin;
Teufel, Martin;
Tewes, Mitra

Publication type:

Article

Plasma Next Generation Sequencing and Droplet Digital-qPCR-Based Quantification of Circulating Cell-Free RNA for Noninvasive Early Detection of Cancer.

Published in:

Cancers, 2020, v. 12, n. 2, p. 353, doi. 10.3390/cancers12020353

By:

Metzenmacher, Martin;
Váraljai, Renáta;
Hegedüs, Balazs;
Cima, Igor;
Forster, Jan;
Schramm, Alexander;
Scheffler, Björn;
Horn, Peter A.;
Klein, Christoph A.;
Szarvas, Tibor;
Reis, Hennig;
Bielefeld, Nicola;
Roesch, Alexander;
Aigner, Clemens;
Kunzmann, Volker;
Wiesweg, Marcel;
Siveke, Jens T.;
Schuler, Martin;
Lueong, Smiths S.

Publication type:

Article

Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor‐positive, HER2‐negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression.

Published in:

Cancer Medicine, 2020, v. 9, n. 13, p. 4527, doi. 10.1002/cam4.3092

By:

Welt, Anja;
Wiesweg, Marcel;
Theurer, Sarah;
Abenhardt, Wolfgang;
Groschek, Matthias;
Müller, Lothar;
Schröder, Jan;
Tewes, Mitra;
Chiabudini, Marco;
Potthoff, Karin;
Bankfalvi, Agnes;
Marschner, Norbert;
Schuler, Martin;
Breitenbücher, Frank

Publication type:

Article

C-reactive protein as robust laboratory value associated with prognosis in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive radiochemotherapy.

Published in:

Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-64302-2

By:

Richlitzki, Cedric;
Wiesweg, Marcel;
Metzenmacher, Martin;
Guberina, Nika;
Pöttgen, Christoph;
Hautzel, Hubertus;
Eberhardt, Wilfried E. E.;
Darwiche, Kaid;
Theegarten, Dirk;
Aigner, Clemens;
Bölükbas, Servet;
Schuler, Martin;
Stuschke, Martin;
Guberina, Maja

Publication type:

Article

Oligometastatic non‐small cell lung cancer: Impact of local and contemporary systemic treatment approaches on clinical outcome.

Published in:

International Journal of Cancer, 2025, v. 156, n. 4, p. 776, doi. 10.1002/ijc.35199

By:

Wiesweg, Marcel;
Küter, Claudia;
Schnorbach, Johannes;
Keyl, Julius;
Metzenmacher, Martin;
Cvetkovic, Jelena;
Saalfeld, Felix Carl;
Glanemann, Franziska;
Eberhardt, Wilfried;
Oezkan, Filiz;
Theegarten, Dirk;
Stenzinger, Albrecht;
Darwiche, Kaid;
Koschel, Dirk;
Herth, Felix;
Bölükbas, Servet;
Winter, Hauke;
Weykamp, Fabian;
Wermke, Martin;
Stuschke, Martin

Publication type:

Article

Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patients.

Published in:

Breast Cancer Research & Treatment, 2013, v. 142, n. 1, p. 81, doi. 10.1007/s10549-013-2718-4

By:

Welt, Anja;
Tewes, Mitra;
Aktas, Bahriye;
Hoffmann, Oliver;
Wiesweg, Marcel;
Ting, Saskia;
Reis, Henning;
Worm, Karl;
Richly, Heike;
Hense, Jörg;
Palmer, Michael;
Lee, Benjamin;
Wendling, Johanna;
Kossow, Josef;
Scheulen, Max;
Lehnerdt, Cathrin;
Kohl, Marzena;
Derks, Cordula;
Skottky, Silke;
Haus, Ulrike

Publication type:

Article

Therapie früher und lokal fortgeschrittener Stadien des nicht-kleinzelligen Lungenkarzinoms.

Published in:

Der Internist, 2022, v. 63, n. 7, p. 717, doi. 10.1007/s00108-022-01366-0

By:

Wiesweg, Marcel;
Eberhardt, Wilfried E.;
Schuler, Martin;
Plönes, Till

Publication type:

Article

Deep learning‐based assessment of body composition and liver tumour burden for survival modelling in advanced colorectal cancer.

Published in:

Journal of Cachexia, Sarcopenia & Muscle, 2023, v. 14, n. 1, p. 545, doi. 10.1002/jcsm.13158

By:

Keyl, Julius;
Hosch, René;
Berger, Aaron;
Ester, Oliver;
Greiner, Tobias;
Bogner, Simon;
Treckmann, Jürgen;
Ting, Saskia;
Schumacher, Brigitte;
Albers, David;
Markus, Peter;
Wiesweg, Marcel;
Forsting, Michael;
Nensa, Felix;
Schuler, Martin;
Kasper, Stefan;
Kleesiek, Jens

Publication type:

Article

ABO‐Blood Group Associates With Survival Outcomes in Patients With Metastatic Non‐Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.

Published in:

Thoracic Cancer, 2025, v. 16, n. 6, p. 1, doi. 10.1111/1759-7714.70037

By:

Certa, Franziska;
Horn, Peter A.;
Keyl, Julius;
Mende, Bastian;
Lueong, Smiths;
Hilser, Thomas;
Theurer, Sarah;
Virchow, Isabel;
Zaun, Yasmin;
Pogorzelski, Michael;
Metzenmacher, Martin;
Kalkavan, Halime;
Kasper, Stefan;
Schuler, Martin;
Wiesweg, Marcel;
Zaun, Gregor

Publication type:

Article

Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial.

Published in:

2020

By:

Kasper, Stefan;
Meiler, Johannes;
Knipp, Heike;
Höhler, Thomas;
Reimer, Peter;
Steinmetz, Tilman;
Berger, Winfried;
Linden, Gabriele;
Reis, Henning;
Markus, Peter;
Paul, Andreas;
Dechêne, Alexander;
Schumacher, Brigitte;
Kostbade, Karina;
Virchow, Isabel;
Ting, Saskia;
Worm, Karl;
Schmid, Kurt W.;
Herold, Thomas;
Wiesweg, Marcel

Publication type:

journal article

Phosphorylation of p70 Ribosomal Protein S6 Kinase β-1 is an Independent Prognostic Parameter in Metastatic Colorectal Cancer.

Published in:

2018

By:

Wiesweg, Marcel;
Reis, Henning;
Köster, Tobias;
Goetz, Moritz;
Worm, Karl;
Herold, Thomas;
Paul, Andreas;
Dechêne, Alexander;
Schumacher, Brigitte;
Markus, Peter;
Virchow, Isabel;
Kostbade, Karina;
Wolf, Nathalie;
Zaun, Gregor;
Metzenmacher, Martin;
Schmid, Kurt W.;
Schuler, Martin;
Kasper, Stefan

Publication type:

journal article

Prediction of malignant lymph nodes in NSCLC by machine-learning classifiers using EBUS-TBNA and PET/CT.

Published in:

Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-21637-y

By:

Guberina, Maja;
Herrmann, Ken;
Pöttgen, Christoph;
Guberina, Nika;
Hautzel, Hubertus;
Gauler, Thomas;
Ploenes, Till;
Umutlu, Lale;
Wetter, Axel;
Theegarten, Dirk;
Aigner, Clemens;
Eberhardt, Wilfried E. E.;
Metzenmacher, Martin;
Wiesweg, Marcel;
Schuler, Martin;
Karpf-Wissel, Rüdiger;
Santiago Garcia, Alina;
Darwiche, Kaid;
Stuschke, Martin

Publication type:

Article

Digital gene expression analysis of NSCLC-patients reveals strong immune pressure, resulting in an immune escape under immunotherapy.

Published in:

BMC Cancer, 2022, v. 22, n. 1, p. 1, doi. 10.1186/s12885-021-09111-w

By:

Wessolly, Michael;
Stephan-Falkenau, Susann;
Streubel, Anna;
Wiesweg, Marcel;
Borchert, Sabrina;
Mairinger, Elena;
Kollmeier, Jens;
Reis, Henning;
Bauer, Torsten;
Schmid, Kurt Werner;
Mairinger, Thomas;
Schuler, Martin;
Mairinger, Fabian D.

Publication type:

Article

Theranostics with somatostatin receptor antagonists in SCLC: Correlation of 68Ga-SSO120 PET with immunohistochemistry and survival.

Published in:

Theranostics, 2024, v. 14, n. 14, p. 5400, doi. 10.7150/thno.98819

By:

Mavroeidi, Ilektra Antonia;
Romanowicz, Anna;
Haake, Tristan;
Wienker, Johannes;
Metzenmacher, Martin;
Darwiche, Kaid;
Oezkan, Filiz;
Bölükbas, Servet;
Stuschke, Martin;
Umutlu, Lale;
Opitz, Marcel;
Nader, Michael;
Hamacher, Rainer;
Siveke, Jens;
Winantea, Jane;
Fendler, Wolfgang P.;
Wiesweg, Marcel;
Eberhardt, Wilfried E. E.;
Herrmann, Ken;
Theegarten, Dirk

Publication type:

Article

Works by Wiesweg, Marcel

Acquired Resistance to BRAF/MEK Inhibitor Therapy in BRAF-V600-mutated Squamous Cell Lung Cancer: Concurrent Evolvement of PTEN and MEK1 Mutations.

Rapid and Highly Sensitive Detection of Therapeutically Relevant Oncogenic Driver Mutations in EBUS-TBNA Specimens From Patients With Lung Adenocarcinoma.

Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting.

Identification of a new prognostic score for patients with high-grade metastatic GEP-NEN treated with palliative chemotherapy.

Improved survival in metastatic breast cancer: results from a 20-year study involving 1033 women treated at a single comprehensive cancer center.

Patterns of nodal spread in stage III NSCLC: importance of EBUS-TBNA and <sup>18</sup>F-FDG PET/CT for radiotherapy target volume definition.

Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2024: Targeted Therapies in Non-Small Cell Lung Cancer.

A Phase II Study of Nab-Paclitaxel and Gemcitabine as First-Line Therapy in Patients with Cholangiocarcinoma Ineligible for Cisplatin-Based Chemotherapy (NACHO).

Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas.

Fibroblast Activation Protein–Directed Imaging Outperforms <sup>18</sup>F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial.

Early Metabolic Response by PET Predicts Sensitivity to Next-Line Targeted Therapy in EGFR-Mutated Lung Cancer with Unknown Mechanism of Acquired Resistance.

<sup>68</sup>Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study.

SUV<sub>max</sub> Above 20 in <sup>18</sup>F-FDG PET/CT at Initial Diagnostic Workup Associates with Favorable Survival in Patients with Cancer of Unknown Primary.

PROGNOSTIC VALUE OF POST-INDUCTION CHEMOTHERAPY VOLUMETRIC PET/CT PARAMETERS FOR STAGE IIIA/B NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING DEFINITIVE CHEMORADIOTHERAPY.

PROGNOSTIC VALUE OF POST-INDUCTION CHEMOTHERAPY VOLUMETRIC PET/CT PARAMETERS FOR STAGE IIIA/B NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING DEFINITIVE CHEMORADIOTHERAPY.

PROGNOSTIC VALUE OF POST-INDUCTION CHEMOTHERAPY VOLUMETRIC PET/CT PARAMETERS FOR STAGE IIIA/B NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING DEFINITIVE CHEMORADIOTHERAPY.

PROGNOSTIC VALUE OF POST-INDUCTION CHEMOTHERAPY VOLUMETRIC PET/CT PARAMETERS FOR STAGE IIIA/B NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING DEFINITIVE CHEMORADIOTHERAPY.

PROGNOSTIC VALUE OF POST-INDUCTION CHEMOTHERAPY VOLUMETRIC PET/CT PARAMETERS FOR STAGE IIIA/B NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING DEFINITIVE CHEMORADIOTHERAPY.

PROGNOSTIC VALUE OF POST-INDUCTION CHEMOTHERAPY VOLUMETRIC PET/CT PARAMETERS FOR STAGE IIIA/B NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING DEFINITIVE CHEMORADIOTHERAPY.

Long-Term Survival in Patients with Oligometastatic Non-Small Cell Lung Cancer by a Multimodality Treatment—Comparison with Stage III Disease.

Electronic Patient-Reported Outcome Measures (ePROMs) Improve the Assessment of Underrated Physical and Psychological Symptom Burden among Oncological Inpatients.

Plasma Next Generation Sequencing and Droplet Digital-qPCR-Based Quantification of Circulating Cell-Free RNA for Noninvasive Early Detection of Cancer.

Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor‐positive, HER2‐negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression.

C-reactive protein as robust laboratory value associated with prognosis in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive radiochemotherapy.

Oligometastatic non‐small cell lung cancer: Impact of local and contemporary systemic treatment approaches on clinical outcome.

Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patients.

Therapie früher und lokal fortgeschrittener Stadien des nicht-kleinzelligen Lungenkarzinoms.

Deep learning‐based assessment of body composition and liver tumour burden for survival modelling in advanced colorectal cancer.

ABO‐Blood Group Associates With Survival Outcomes in Patients With Metastatic Non‐Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.

Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial.

Phosphorylation of p70 Ribosomal Protein S6 Kinase β-1 is an Independent Prognostic Parameter in Metastatic Colorectal Cancer.

Prediction of malignant lymph nodes in NSCLC by machine-learning classifiers using EBUS-TBNA and PET/CT.

Digital gene expression analysis of NSCLC-patients reveals strong immune pressure, resulting in an immune escape under immunotherapy.

Theranostics with somatostatin receptor antagonists in SCLC: Correlation of <sup>68</sup>Ga-SSO120 PET with immunohistochemistry and survival.